NCT07169734View on ClinicalTrials.gov

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

August 26, 2025

Primary Completion Date

April 5, 2029

Study Completion Date

October 4, 2029

Conditions
Cervical Squamous Cell CarcinomaSquamous Non-small-cell Lung CancerColorectal CancerIntrahepatic CholangiocarcinomaUrothelial Carcinoma
Interventions
DRUG

ALE.P03

ALE.P03, will be administered by IV infusion according to the assigned arms.

DRUG

ALE.P03

ALE.P03, will be administered by IV infusion according to the assigned arms.

DRUG

ALE.P03

ALE.P03, will be administered by IV infusion according to the assigned arms.

Trial Locations (2)

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

78229

RECRUITING

Next Oncology-Oncology, San Antonio

Sponsors
All Listed Sponsors
lead

Alentis Therapeutics AG

INDUSTRY

NCT07169734 - A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | Biotech Hunter | Biotech Hunter